Number of Disaggregated unit cost units of resource Setting in per relevant Proportion which time Patient of patients MBS/PBS Other Private resource horizon per Provider of Safety receiving Schedule govt health is patient resource cost resource Fee budget insurer provided receiving resource Arm 1 % to be TBD on Re-testing evidence or clinical opinion Resources provided to deliver proposed intervention: Proposed drug (lapatinib) + co-administered (taxane) Lapatinib Medical Outpatient/ HER2 Number of Cost/tablet TBD oncologist inpatient positivity tablets/ 250mg tablet c-in-c rate patientb (patients eligible for lapatinib) DOCETAXEL Medical Outpatient/ % to be Number of Cost/ TBD Solution oncologist inpatient based on infusions/ infusion concentrate for IV patientb $34.20 infusion 20 mg in evidence or 1 mL clinical opinion PACLITAXEL Medical Outpatient/ % to be Number of Cost/ TBD Solution oncologist inpatient based on infusions/ infusion concentrate for IV patientb $34.20 infusion 150 mg in evidence or 25 mL clinical opinion Drug Medical Day patient % to be Number of Cost/ TBD administration cost oncologist on health infusions/ infusion for 1 to 6 hour service patientc infusion in usage data MBS item outpatient setting or clinical number opinion 13918 $94.20 Full day hospital Medical Day patient % to be Number of Cost/ TBD admission for oncologist on health infusions/ infusion chemotherapy in a service patientc public hospital usage data $516 setting (excluding or clinical average pharmacy opinion cost component)d Full day hospital Medical Day patient % to be Number of Cost/ TBD admission for oncologist based on infusions/ infusion chemotherapy in a health patientc private hospital service $310 setting (excluding usage data average pharmacy or clinical cost component)d opinion Resources provided to deliver proposed intervention: Cardiac monitoring for patients receiving lapatinib Echocardiogram Outpatient % to be Number of Cost/ TBD based on procedures/ procedure patient evidence or MBS item clinical number opinion
Setting in which resource is provided Proportion of patients receiving resource Number of units of resource per relevant time horizon per patient receiving resource Disaggregated unit cost Provider of resource MBS/PBS Schedule Fee Safety Other govt budget Private health insurer Patient cost Arm 1 Re-testing % to be on evidence or clinical opinion TBD Resources provided to deliver proposed intervention: Proposed drug (lapatinib) + co-administered (taxane) Lapatinib 250mg tablet Medical oncologist Outpatient/ inpatient HER2 positivity rate (patients eligible for lapatinib) Number of tablets/ patientb Cost/tablet c-in-c TBD DOCETAXEL Solution concentrate for IV infusion 20 mg in 1 mL Medical oncologist Outpatient/ inpatient % to be based on evidence or clinical opinion Number of infusions/ patientb Cost/ infusion $34.20 TBD PACLITAXEL Solution concentrate for IV infusion 150 mg in 25 mL Medical oncologist Outpatient/ inpatient % to be based on evidence or clinical opinion Number of infusions/ patientb Cost/ infusion $34.20 TBD Drug administration cost for 1 to 6 hour infusion in outpatient setting Medical oncologist Day patient % to be on health service usage data or clinical opinion Number of infusions/ patientc Cost/ infusion MBS item number 13918 $94.20 TBD Full day hospital admission for chemotherapy in a public hospital setting (excluding average pharmacy cost component)d Medical oncologist Day patient % to be on health service usage data or clinical opinion Number of infusions/ patientc Cost/ infusion $516 TBD Full day hospital admission for chemotherapy in a private hospital setting (excluding average pharmacy cost component)d Medical oncologist Day patient % to be based on health service usage data or clinical opinion Number of infusions/ patientc Cost/ infusion $310 TBD Resources provided to deliver proposed intervention: Cardiac monitoring for patients receiving lapatinib Echocardiogram Outpatient % to be based on evidence or clinical opinion Number of procedures/ patient Cost/ procedure MBS item number TBD
1175-HER2-for-Lapatnib-Final-DAP-Accessible.docx